Overview: Obesity Panel
Introduction: The Obesity Panel is a diagnostic tool designed to assess obesity-related markers using serum samples. In India, obesity (BMI ≥25) affects ~20-30 percent of urban adults and ~10-15 percent rural (rising rapidly), driving type 2 diabetes (~77 million cases), NAFLD, CVD, and metabolic syndrome. High morbidity from under-testing in rural/low-SES populations with central obesity, limited labs, delayed lifestyle/pharmacotherapy leading to complications. Per endocrinology practices aligned with ICMR, RSSDI, and National Programme for Prevention and Control of Cancer, Diabetes, CVD and Stroke guidelines, the test employs spectrophotometry for lipid profile, fasting glucose, insulin, cortisol, leptin, TSH, HbA1c, and CRP over 1-2 days with high accuracy, valuable for metabolic risk stratification. This diagnostic falls under metabolic screening and targets overweight/obese individuals or those with metabolic risk, addressing accurate detection to guide diet, exercise, metformin, or bariatric referral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise obesity profiling and reducing NCD burden. Its serum-based approach ensures reliable multi-marker assessment.
Other Names: Obesity Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.
Historical Milestone: Metabolic obesity panel standard; in India, key in NCD programs.
Purpose: The test assesses 8 parameters including lipid profile to guide obesity assessment, detect metabolic abnormalities, inform intervention.
Test Parameters: 1. Lipid Profile, 2. Fasting Glucose, 3. Insulin, 4. Cortisol, 5. Leptin, 6. TSH, 7. HbA1c, 8. CRP.
Pretest Condition: Fasting 10-12 hours required; patients should report weight gain or metabolic symptoms.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on BMI, diet, family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected metabolic issues including diabetes, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal insulin/leptin/HbA1c indicates metabolic dysfunction, necessitating specialist input.
Specialist Consultation: Endocrinologists or physicians should be consulted for management.
Additional Supporting Tests: HOMA-IR, waist circumference for confirmation.
Test Limitations: Fasting critical; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Obesity Studies India 2023.
